Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
$19.84
-1.4%
$17.99
$15.45
$35.84
$580.91M1.1420,593 shs282,935 shs
DermTech, Inc. stock logo
DMTK
DermTech
$0.19
$0.09
$3.90
$3.29M2.481.07 million shs3.66 million shs
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
$19.55
-0.2%
$20.23
$14.57
$25.11
$596.09M1.03286,215 shs219,928 shs
RadNet, Inc. stock logo
RDNT
RadNet
$57.50
-0.2%
$57.00
$45.00
$93.65
$4.32B1.41683,024 shs485,551 shs
Renalytix Plc stock logo
RNLX
Renalytix
$0.21
$0.23
$0.18
$2.40
$17.18M2.721.45 million shs934,496 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
-1.39%-2.19%+9.98%+0.71%+13.50%
DermTech, Inc. stock logo
DMTK
DermTech
0.00%0.00%0.00%0.00%+6.45%
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
-0.15%-2.54%-10.24%+2.89%-0.26%
RadNet, Inc. stock logo
RDNT
RadNet
-0.21%+2.39%-3.02%+7.66%+2.28%
Renalytix Plc stock logo
RNLX
Renalytix
0.00%0.00%0.00%0.00%-31.40%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
3.0754 of 5 stars
3.54.00.00.02.62.50.0
DermTech, Inc. stock logo
DMTK
DermTech
N/AN/AN/AN/AN/AN/AN/AN/A
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
3.6413 of 5 stars
2.31.00.04.12.73.30.6
RadNet, Inc. stock logo
RDNT
RadNet
3.9343 of 5 stars
2.82.00.04.63.52.50.0
Renalytix Plc stock logo
RNLX
Renalytix
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
3.00
Buy$37.0086.49% Upside
DermTech, Inc. stock logo
DMTK
DermTech
0.00
N/AN/AN/A
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
2.50
Moderate Buy$24.0022.76% Upside
RadNet, Inc. stock logo
RDNT
RadNet
3.50
Strong Buy$69.6021.04% Upside
Renalytix Plc stock logo
RNLX
Renalytix
3.00
Buy$3.001,348.58% Upside

Current Analyst Ratings Breakdown

Latest RDNT, DMTK, RNLX, CSTL, and FLGT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/10/2025
RadNet, Inc. stock logo
RDNT
RadNet
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$74.00
6/13/2025
RadNet, Inc. stock logo
RDNT
RadNet
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy ➝ Buy$69.00
6/12/2025
RadNet, Inc. stock logo
RDNT
RadNet
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy ➝ Strong-Buy
5/21/2025
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Outperform ➝ Sector Outperform$44.00 ➝ $40.00
5/6/2025
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$16.00 ➝ $23.00
5/6/2025
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$40.00 ➝ $35.00
5/6/2025
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$42.00 ➝ $37.00
5/5/2025
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$24.00 ➝ $25.00
4/11/2025
RadNet, Inc. stock logo
RDNT
RadNet
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$88.00 ➝ $74.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
$332.07M1.72$0.97 per share20.45$16.28 per share1.22
DermTech, Inc. stock logo
DMTK
DermTech
$15.66M0.00N/AN/A$1.67 per share0.00
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
$283.47M2.10N/AN/A$36.92 per share0.53
RadNet, Inc. stock logo
RDNT
RadNet
$1.87B2.31$3.48 per share16.54$15.31 per share3.76
Renalytix Plc stock logo
RNLX
Renalytix
$2.29M7.50N/AN/A($0.10) per share-2.07
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
$18.25M-$0.19N/AN/AN/A-1.46%3.41%2.95%8/4/2025 (Estimated)
DermTech, Inc. stock logo
DMTK
DermTech
-$100.89M-$2.70N/AN/AN/A-572.19%-138.79%-68.96%N/A
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
-$42.71M-$1.33N/AN/AN/A-13.94%-2.19%-2.02%8/1/2025 (Estimated)
RadNet, Inc. stock logo
RDNT
RadNet
$2.79M-$0.43N/A108.49N/A-1.73%1.41%0.48%8/6/2025 (Estimated)
Renalytix Plc stock logo
RNLX
Renalytix
-$33.46M-$0.39N/AN/A-1,461.60%N/A-281.40%N/A

Latest RDNT, DMTK, RNLX, CSTL, and FLGT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
RadNet, Inc. stock logo
RDNT
RadNet
$0.17N/AN/AN/A$488.06 millionN/A
8/4/2025Q2 2025
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
-$0.44N/AN/AN/A$71.53 millionN/A
8/1/2025Q2 2025
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
-$0.23N/AN/AN/A$76.21 millionN/A
5/5/2025Q1 2025
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
-$0.08-$0.20-$0.12-$0.90$80.40 million$87.99 million
5/2/2025Q1 2025
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
-$0.18$0.04+$0.22-$0.37$71.26 million$73.46 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
N/AN/AN/AN/AN/A
DermTech, Inc. stock logo
DMTK
DermTech
N/AN/AN/AN/AN/A
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
N/AN/AN/AN/AN/A
RadNet, Inc. stock logo
RDNT
RadNet
N/AN/AN/AN/AN/A
Renalytix Plc stock logo
RNLX
Renalytix
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
0.02
9.37
9.19
DermTech, Inc. stock logo
DMTK
DermTech
N/A
3.53
3.46
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
N/A
6.32
6.32
RadNet, Inc. stock logo
RDNT
RadNet
0.87
2.01
2.01
Renalytix Plc stock logo
RNLX
Renalytix
N/A
0.53
0.53

Institutional Ownership

CompanyInstitutional Ownership
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
92.60%
DermTech, Inc. stock logo
DMTK
DermTech
20.45%
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
48.06%
RadNet, Inc. stock logo
RDNT
RadNet
77.90%
Renalytix Plc stock logo
RNLX
Renalytix
9.92%

Insider Ownership

CompanyInsider Ownership
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
6.50%
DermTech, Inc. stock logo
DMTK
DermTech
5.10%
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
31.76%
RadNet, Inc. stock logo
RDNT
RadNet
5.60%
Renalytix Plc stock logo
RNLX
Renalytix
18.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
54028.87 million27.00 millionOptionable
DermTech, Inc. stock logo
DMTK
DermTech
26034.96 million33.18 millionOptionable
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
1,31330.44 million20.78 millionOptionable
RadNet, Inc. stock logo
RDNT
RadNet
11,02175.03 million70.83 millionOptionable
Renalytix Plc stock logo
RNLX
Renalytix
10082.96 million63.06 millionOptionable

Recent News About These Companies

Renalytix Adjusts Share Capital Amid Fundraising Shortfall
Renalytix AI earnings: here's what Wall Street expects

New MarketBeat Followers Over Time

Media Sentiment Over Time

Castle Biosciences stock logo

Castle Biosciences NASDAQ:CSTL

$19.84 -0.28 (-1.39%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$19.77 -0.07 (-0.33%)
As of 04:55 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

DermTech stock logo

DermTech NASDAQ:DMTK

DermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the psoriasis, atopic dermatitis, and aging of the skin to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California.

Fulgent Genetics stock logo

Fulgent Genetics NASDAQ:FLGT

$19.55 -0.03 (-0.15%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$19.43 -0.12 (-0.63%)
As of 05:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.

RadNet stock logo

RadNet NASDAQ:RDNT

$57.50 -0.12 (-0.21%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$57.42 -0.08 (-0.14%)
As of 05:44 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.

Renalytix stock logo

Renalytix NASDAQ:RNLX

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix Plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; and Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is based in New York, New York.